doi,publication_date,review_type,review_group,review_mesh_keywords,title,authors,publish_type,is_most_recent_version,url_most_most_version,main_comparison_of_review,main_comparison_population,main_comparison_setting,main_comparison_comparsion_type,background,objectives,search_methods,selection_criteria,data_coll_analysis,main_results,conclusions,summaryTable_count,GRADE_somewhere_in_the_text,is_paywalled,id_measure,Outcomes,relative_effect_95CI,n_participants_studies,GRADE,Comments,effect_statistic,n_participants,n_studies,CI_lower,CI_upper,effect_size,warnings
https://doi.org/10.1002/14651858.CD012941.pub2,18 June 2019,Intervention,Cochrane Acute Respiratory Infections Group,"Keywords


Medical Subject Headings (MeSH) Keywords

Acute Disease;
Anti‐Bacterial Agents [therapeutic use];
Disease Susceptibility;
Otitis Media [epidemiology, *prevention & control];
Probiotics [adverse effects, *therapeutic use];
Randomized Controlled Trials as Topic [statistics & numerical data];



Medical Subject Headings Check Words

Adolescent;
Child;
Child, Preschool;
Humans;
Infant;



",Probiotics for preventing acute otitis media in children,"Anna M Scott, Justin Clark, Blair Julien, Farhana Islam, Kristian Roos, Keith Grimwood, Paul Little, Chris B Del Mar",Review - Intervention,TRUE,NA,Probiotic compared to placebo for preventing acute otitis media in children,children up to age 18 years,"community, primary care, and secondary care",comparator," Acute otitis media (AOM), or acute middle ear infection, is one of the most frequently occurring childhood diseases, and the most common reason given for prescribing antibiotics in this age group. Guidelines often recommend antibiotics as first‐line treatment for severe AOM. However, antibiotics also lead to antibiotic resistance, so preventing episodes of AOM is an urgent priority.  ", To assess the effects of probiotics to prevent the occurrence and reduce the severity of acute otitis media in children.  ," We searched CENTRAL, PubMed, Embase, and three other databases (October 2018), two trial registers (October 2018), and conducted a backwards and forwards citation analysis (August 2018). We did not apply any language, publication date, or publication status restrictions.  "," We searched CENTRAL, PubMed, Embase, and three other databases (October 2018), two trial registers (October 2018), and conducted a backwards and forwards citation analysis (August 2018). We did not apply any language, publication date, or publication status restrictions.  Selection criteria Randomised controlled trials (RCTs) of children (aged up to 18 years), comparing probiotics with placebo, usual care, or no probiotic.  "," Two review authors independently assessed the eligibility of trials for inclusion and risk of bias of the included trials, and extracted data using pre‐piloted data extraction forms. We analysed dichotomous data as either risk ratio (RR) or odds ratios (OR) and continuous data as mean differences (MD).  "," We included 17 RCTs involving 3488 children, of which 16 RCTs were included in the meta‐analyses. Of the 16 RCTs that reported the mean age of children, mean age overall was 2.4 years; in 4 RCTs the mean age of children participating in the trial was less than 1 year old; in 2 RCTs the mean age was between 1 and 2 years old; and in 10 RCTs the mean age was older than 2 years. Probiotic strains evaluated by the trials varied, with 11 of the included RCTs evaluating Lactobacillus‐containing probiotics, and six RCTs evaluating Streptococcus‐containing probiotics.  The proportion of children (i.e. the number of children in each group) experiencing one or more episodes of AOM during the treatment was lower for those taking probiotics (RR 0.77, 95% confidence interval (CI) 0.63 to 0.93; 16 trials; 2961 participants; number needed to treat for an additional beneficial outcome (NNTB) = 10; moderate‐certainty evidence).  Post hoc subgroup analysis found that among children not prone to otitis media, a lower proportion of children receiving probiotics experienced AOM (RR 0.64, 95% CI 0.49 to 0.84; 11 trials; 2227 participants; NNTB = 9; moderate‐certainty evidence). However, among children who were otitis prone, there was no difference between probiotic and comparator groups (RR 0.97, 95% CI 0.85 to 1.11; 5 trials; 734 participants; high‐certainty evidence). The test for subgroup differences was significant (P = 0.007).  None of the included trials reported on the severity of AOM. The proportion of children experiencing adverse events did not differ between the probiotic and comparator groups (OR 1.54, 95% CI 0.60 to 3.94; 4 trials; 395 participants; low‐certainty evidence).  Probiotics decreased the proportion of children taking antibiotics for any infection (RR 0.66, 95% CI 0.51 to 0.86; 8 trials; 1768 participants; NNTB = 8; moderate‐certainty evidence). Test for subgroup differences (use of antibiotic specifically for AOM, use of antibiotic for infections other than AOM) was not significant.  There was no difference in the mean number of school days lost (MD −0.95, 95% CI −2.47 to 0.57; 5 trials; 1280 participants; moderate‐certainty evidence). There was no difference between groups in the level of compliance in taking the intervention (RR 1.02, 95% CI 0.99 to 1.05; 5 trials; 990 participants).  Probiotics decreased the proportion of children having other infections (RR 0.75, 95% CI 0.65 to 0.87; 11 trials; 3610 participants; NNTB = 12; moderate‐certainty evidence). Test for subgroup differences (acute respiratory infections, gastrointestinal infections) was not significant.  Probiotic strains trialled and their dose, frequency, and duration of administration varied considerably across studies, which likely contributed to the substantial levels of heterogeneity. Sensitivity testing of funnel plots did not reveal publication bias.  "," Probiotics may prevent AOM in children not prone to AOM, but the inconsistency of the subgroup analyses suggests caution in interpreting these results. Probiotics decreased the proportion of children taking antibiotics for any infection. The proportion of children experiencing adverse events did not differ between the probiotic and comparator groups. The optimal strain, duration, frequency, and timing of probiotic administration still needs to be established.   ",1,TRUE,FALSE,1,Proportion of children with AOM (overall),RR 0.77 (0.63 to 0.93),2961 (16 RCTs),⊕⊕⊕⊝ MODERATE1,We conducted a post hoc sensitivity analysis by health status (children prone to AOM versus children not prone to AOM). The test for subgroup differences was significant (P = 0.007). The follow‐up duration ranged from 20 days to 2 years.,RR,2961,16,0.63,0.93,RR 0.77,Initializing
https://doi.org/10.1002/14651858.CD012941.pub2,18 June 2019,Intervention,Cochrane Acute Respiratory Infections Group,"Keywords


Medical Subject Headings (MeSH) Keywords

Acute Disease;
Anti‐Bacterial Agents [therapeutic use];
Disease Susceptibility;
Otitis Media [epidemiology, *prevention & control];
Probiotics [adverse effects, *therapeutic use];
Randomized Controlled Trials as Topic [statistics & numerical data];



Medical Subject Headings Check Words

Adolescent;
Child;
Child, Preschool;
Humans;
Infant;



",Probiotics for preventing acute otitis media in children,"Anna M Scott, Justin Clark, Blair Julien, Farhana Islam, Kristian Roos, Keith Grimwood, Paul Little, Chris B Del Mar",Review - Intervention,TRUE,NA,Probiotic compared to placebo for preventing acute otitis media in children,children up to age 18 years,"community, primary care, and secondary care",comparator," Acute otitis media (AOM), or acute middle ear infection, is one of the most frequently occurring childhood diseases, and the most common reason given for prescribing antibiotics in this age group. Guidelines often recommend antibiotics as first‐line treatment for severe AOM. However, antibiotics also lead to antibiotic resistance, so preventing episodes of AOM is an urgent priority.  ", To assess the effects of probiotics to prevent the occurrence and reduce the severity of acute otitis media in children.  ," We searched CENTRAL, PubMed, Embase, and three other databases (October 2018), two trial registers (October 2018), and conducted a backwards and forwards citation analysis (August 2018). We did not apply any language, publication date, or publication status restrictions.  "," We searched CENTRAL, PubMed, Embase, and three other databases (October 2018), two trial registers (October 2018), and conducted a backwards and forwards citation analysis (August 2018). We did not apply any language, publication date, or publication status restrictions.  Selection criteria Randomised controlled trials (RCTs) of children (aged up to 18 years), comparing probiotics with placebo, usual care, or no probiotic.  "," Two review authors independently assessed the eligibility of trials for inclusion and risk of bias of the included trials, and extracted data using pre‐piloted data extraction forms. We analysed dichotomous data as either risk ratio (RR) or odds ratios (OR) and continuous data as mean differences (MD).  "," We included 17 RCTs involving 3488 children, of which 16 RCTs were included in the meta‐analyses. Of the 16 RCTs that reported the mean age of children, mean age overall was 2.4 years; in 4 RCTs the mean age of children participating in the trial was less than 1 year old; in 2 RCTs the mean age was between 1 and 2 years old; and in 10 RCTs the mean age was older than 2 years. Probiotic strains evaluated by the trials varied, with 11 of the included RCTs evaluating Lactobacillus‐containing probiotics, and six RCTs evaluating Streptococcus‐containing probiotics.  The proportion of children (i.e. the number of children in each group) experiencing one or more episodes of AOM during the treatment was lower for those taking probiotics (RR 0.77, 95% confidence interval (CI) 0.63 to 0.93; 16 trials; 2961 participants; number needed to treat for an additional beneficial outcome (NNTB) = 10; moderate‐certainty evidence).  Post hoc subgroup analysis found that among children not prone to otitis media, a lower proportion of children receiving probiotics experienced AOM (RR 0.64, 95% CI 0.49 to 0.84; 11 trials; 2227 participants; NNTB = 9; moderate‐certainty evidence). However, among children who were otitis prone, there was no difference between probiotic and comparator groups (RR 0.97, 95% CI 0.85 to 1.11; 5 trials; 734 participants; high‐certainty evidence). The test for subgroup differences was significant (P = 0.007).  None of the included trials reported on the severity of AOM. The proportion of children experiencing adverse events did not differ between the probiotic and comparator groups (OR 1.54, 95% CI 0.60 to 3.94; 4 trials; 395 participants; low‐certainty evidence).  Probiotics decreased the proportion of children taking antibiotics for any infection (RR 0.66, 95% CI 0.51 to 0.86; 8 trials; 1768 participants; NNTB = 8; moderate‐certainty evidence). Test for subgroup differences (use of antibiotic specifically for AOM, use of antibiotic for infections other than AOM) was not significant.  There was no difference in the mean number of school days lost (MD −0.95, 95% CI −2.47 to 0.57; 5 trials; 1280 participants; moderate‐certainty evidence). There was no difference between groups in the level of compliance in taking the intervention (RR 1.02, 95% CI 0.99 to 1.05; 5 trials; 990 participants).  Probiotics decreased the proportion of children having other infections (RR 0.75, 95% CI 0.65 to 0.87; 11 trials; 3610 participants; NNTB = 12; moderate‐certainty evidence). Test for subgroup differences (acute respiratory infections, gastrointestinal infections) was not significant.  Probiotic strains trialled and their dose, frequency, and duration of administration varied considerably across studies, which likely contributed to the substantial levels of heterogeneity. Sensitivity testing of funnel plots did not reveal publication bias.  "," Probiotics may prevent AOM in children not prone to AOM, but the inconsistency of the subgroup analyses suggests caution in interpreting these results. Probiotics decreased the proportion of children taking antibiotics for any infection. The proportion of children experiencing adverse events did not differ between the probiotic and comparator groups. The optimal strain, duration, frequency, and timing of probiotic administration still needs to be established.   ",1,TRUE,FALSE,2,Proportion of children with AOM (overall),RR 0.77 (0.63 to 0.93),2961 (16 RCTs),⊕⊕⊕⊝ MODERATE1,300 per 1000 (246 to 362),RR,2961,16,0.63,0.93,RR 0.77,Initializing
https://doi.org/10.1002/14651858.CD012941.pub2,18 June 2019,Intervention,Cochrane Acute Respiratory Infections Group,"Keywords


Medical Subject Headings (MeSH) Keywords

Acute Disease;
Anti‐Bacterial Agents [therapeutic use];
Disease Susceptibility;
Otitis Media [epidemiology, *prevention & control];
Probiotics [adverse effects, *therapeutic use];
Randomized Controlled Trials as Topic [statistics & numerical data];



Medical Subject Headings Check Words

Adolescent;
Child;
Child, Preschool;
Humans;
Infant;



",Probiotics for preventing acute otitis media in children,"Anna M Scott, Justin Clark, Blair Julien, Farhana Islam, Kristian Roos, Keith Grimwood, Paul Little, Chris B Del Mar",Review - Intervention,TRUE,NA,Probiotic compared to placebo for preventing acute otitis media in children,children up to age 18 years,"community, primary care, and secondary care",comparator," Acute otitis media (AOM), or acute middle ear infection, is one of the most frequently occurring childhood diseases, and the most common reason given for prescribing antibiotics in this age group. Guidelines often recommend antibiotics as first‐line treatment for severe AOM. However, antibiotics also lead to antibiotic resistance, so preventing episodes of AOM is an urgent priority.  ", To assess the effects of probiotics to prevent the occurrence and reduce the severity of acute otitis media in children.  ," We searched CENTRAL, PubMed, Embase, and three other databases (October 2018), two trial registers (October 2018), and conducted a backwards and forwards citation analysis (August 2018). We did not apply any language, publication date, or publication status restrictions.  "," We searched CENTRAL, PubMed, Embase, and three other databases (October 2018), two trial registers (October 2018), and conducted a backwards and forwards citation analysis (August 2018). We did not apply any language, publication date, or publication status restrictions.  Selection criteria Randomised controlled trials (RCTs) of children (aged up to 18 years), comparing probiotics with placebo, usual care, or no probiotic.  "," Two review authors independently assessed the eligibility of trials for inclusion and risk of bias of the included trials, and extracted data using pre‐piloted data extraction forms. We analysed dichotomous data as either risk ratio (RR) or odds ratios (OR) and continuous data as mean differences (MD).  "," We included 17 RCTs involving 3488 children, of which 16 RCTs were included in the meta‐analyses. Of the 16 RCTs that reported the mean age of children, mean age overall was 2.4 years; in 4 RCTs the mean age of children participating in the trial was less than 1 year old; in 2 RCTs the mean age was between 1 and 2 years old; and in 10 RCTs the mean age was older than 2 years. Probiotic strains evaluated by the trials varied, with 11 of the included RCTs evaluating Lactobacillus‐containing probiotics, and six RCTs evaluating Streptococcus‐containing probiotics.  The proportion of children (i.e. the number of children in each group) experiencing one or more episodes of AOM during the treatment was lower for those taking probiotics (RR 0.77, 95% confidence interval (CI) 0.63 to 0.93; 16 trials; 2961 participants; number needed to treat for an additional beneficial outcome (NNTB) = 10; moderate‐certainty evidence).  Post hoc subgroup analysis found that among children not prone to otitis media, a lower proportion of children receiving probiotics experienced AOM (RR 0.64, 95% CI 0.49 to 0.84; 11 trials; 2227 participants; NNTB = 9; moderate‐certainty evidence). However, among children who were otitis prone, there was no difference between probiotic and comparator groups (RR 0.97, 95% CI 0.85 to 1.11; 5 trials; 734 participants; high‐certainty evidence). The test for subgroup differences was significant (P = 0.007).  None of the included trials reported on the severity of AOM. The proportion of children experiencing adverse events did not differ between the probiotic and comparator groups (OR 1.54, 95% CI 0.60 to 3.94; 4 trials; 395 participants; low‐certainty evidence).  Probiotics decreased the proportion of children taking antibiotics for any infection (RR 0.66, 95% CI 0.51 to 0.86; 8 trials; 1768 participants; NNTB = 8; moderate‐certainty evidence). Test for subgroup differences (use of antibiotic specifically for AOM, use of antibiotic for infections other than AOM) was not significant.  There was no difference in the mean number of school days lost (MD −0.95, 95% CI −2.47 to 0.57; 5 trials; 1280 participants; moderate‐certainty evidence). There was no difference between groups in the level of compliance in taking the intervention (RR 1.02, 95% CI 0.99 to 1.05; 5 trials; 990 participants).  Probiotics decreased the proportion of children having other infections (RR 0.75, 95% CI 0.65 to 0.87; 11 trials; 3610 participants; NNTB = 12; moderate‐certainty evidence). Test for subgroup differences (acute respiratory infections, gastrointestinal infections) was not significant.  Probiotic strains trialled and their dose, frequency, and duration of administration varied considerably across studies, which likely contributed to the substantial levels of heterogeneity. Sensitivity testing of funnel plots did not reveal publication bias.  "," Probiotics may prevent AOM in children not prone to AOM, but the inconsistency of the subgroup analyses suggests caution in interpreting these results. Probiotics decreased the proportion of children taking antibiotics for any infection. The proportion of children experiencing adverse events did not differ between the probiotic and comparator groups. The optimal strain, duration, frequency, and timing of probiotic administration still needs to be established.   ",1,TRUE,FALSE,3,Proportion of children with AOM: children not prone to AOM,RR 0.64 (0.49 to 0.84),2227 (11 RCTs),⊕⊕⊕⊝ MODERATE2,The follow‐up duration ranged from 20 days to 2 years.,RR,2227,11,0.49,0.84,RR 0.64,Initializing
https://doi.org/10.1002/14651858.CD012941.pub2,18 June 2019,Intervention,Cochrane Acute Respiratory Infections Group,"Keywords


Medical Subject Headings (MeSH) Keywords

Acute Disease;
Anti‐Bacterial Agents [therapeutic use];
Disease Susceptibility;
Otitis Media [epidemiology, *prevention & control];
Probiotics [adverse effects, *therapeutic use];
Randomized Controlled Trials as Topic [statistics & numerical data];



Medical Subject Headings Check Words

Adolescent;
Child;
Child, Preschool;
Humans;
Infant;



",Probiotics for preventing acute otitis media in children,"Anna M Scott, Justin Clark, Blair Julien, Farhana Islam, Kristian Roos, Keith Grimwood, Paul Little, Chris B Del Mar",Review - Intervention,TRUE,NA,Probiotic compared to placebo for preventing acute otitis media in children,children up to age 18 years,"community, primary care, and secondary care",comparator," Acute otitis media (AOM), or acute middle ear infection, is one of the most frequently occurring childhood diseases, and the most common reason given for prescribing antibiotics in this age group. Guidelines often recommend antibiotics as first‐line treatment for severe AOM. However, antibiotics also lead to antibiotic resistance, so preventing episodes of AOM is an urgent priority.  ", To assess the effects of probiotics to prevent the occurrence and reduce the severity of acute otitis media in children.  ," We searched CENTRAL, PubMed, Embase, and three other databases (October 2018), two trial registers (October 2018), and conducted a backwards and forwards citation analysis (August 2018). We did not apply any language, publication date, or publication status restrictions.  "," We searched CENTRAL, PubMed, Embase, and three other databases (October 2018), two trial registers (October 2018), and conducted a backwards and forwards citation analysis (August 2018). We did not apply any language, publication date, or publication status restrictions.  Selection criteria Randomised controlled trials (RCTs) of children (aged up to 18 years), comparing probiotics with placebo, usual care, or no probiotic.  "," Two review authors independently assessed the eligibility of trials for inclusion and risk of bias of the included trials, and extracted data using pre‐piloted data extraction forms. We analysed dichotomous data as either risk ratio (RR) or odds ratios (OR) and continuous data as mean differences (MD).  "," We included 17 RCTs involving 3488 children, of which 16 RCTs were included in the meta‐analyses. Of the 16 RCTs that reported the mean age of children, mean age overall was 2.4 years; in 4 RCTs the mean age of children participating in the trial was less than 1 year old; in 2 RCTs the mean age was between 1 and 2 years old; and in 10 RCTs the mean age was older than 2 years. Probiotic strains evaluated by the trials varied, with 11 of the included RCTs evaluating Lactobacillus‐containing probiotics, and six RCTs evaluating Streptococcus‐containing probiotics.  The proportion of children (i.e. the number of children in each group) experiencing one or more episodes of AOM during the treatment was lower for those taking probiotics (RR 0.77, 95% confidence interval (CI) 0.63 to 0.93; 16 trials; 2961 participants; number needed to treat for an additional beneficial outcome (NNTB) = 10; moderate‐certainty evidence).  Post hoc subgroup analysis found that among children not prone to otitis media, a lower proportion of children receiving probiotics experienced AOM (RR 0.64, 95% CI 0.49 to 0.84; 11 trials; 2227 participants; NNTB = 9; moderate‐certainty evidence). However, among children who were otitis prone, there was no difference between probiotic and comparator groups (RR 0.97, 95% CI 0.85 to 1.11; 5 trials; 734 participants; high‐certainty evidence). The test for subgroup differences was significant (P = 0.007).  None of the included trials reported on the severity of AOM. The proportion of children experiencing adverse events did not differ between the probiotic and comparator groups (OR 1.54, 95% CI 0.60 to 3.94; 4 trials; 395 participants; low‐certainty evidence).  Probiotics decreased the proportion of children taking antibiotics for any infection (RR 0.66, 95% CI 0.51 to 0.86; 8 trials; 1768 participants; NNTB = 8; moderate‐certainty evidence). Test for subgroup differences (use of antibiotic specifically for AOM, use of antibiotic for infections other than AOM) was not significant.  There was no difference in the mean number of school days lost (MD −0.95, 95% CI −2.47 to 0.57; 5 trials; 1280 participants; moderate‐certainty evidence). There was no difference between groups in the level of compliance in taking the intervention (RR 1.02, 95% CI 0.99 to 1.05; 5 trials; 990 participants).  Probiotics decreased the proportion of children having other infections (RR 0.75, 95% CI 0.65 to 0.87; 11 trials; 3610 participants; NNTB = 12; moderate‐certainty evidence). Test for subgroup differences (acute respiratory infections, gastrointestinal infections) was not significant.  Probiotic strains trialled and their dose, frequency, and duration of administration varied considerably across studies, which likely contributed to the substantial levels of heterogeneity. Sensitivity testing of funnel plots did not reveal publication bias.  "," Probiotics may prevent AOM in children not prone to AOM, but the inconsistency of the subgroup analyses suggests caution in interpreting these results. Probiotics decreased the proportion of children taking antibiotics for any infection. The proportion of children experiencing adverse events did not differ between the probiotic and comparator groups. The optimal strain, duration, frequency, and timing of probiotic administration still needs to be established.   ",1,TRUE,FALSE,4,Proportion of children with AOM: children not prone to AOM,RR 0.64 (0.49 to 0.84),2227 (11 RCTs),⊕⊕⊕⊝ MODERATE2,189 per 1000 (145 to 248),RR,2227,11,0.49,0.84,RR 0.64,Initializing
https://doi.org/10.1002/14651858.CD012941.pub2,18 June 2019,Intervention,Cochrane Acute Respiratory Infections Group,"Keywords


Medical Subject Headings (MeSH) Keywords

Acute Disease;
Anti‐Bacterial Agents [therapeutic use];
Disease Susceptibility;
Otitis Media [epidemiology, *prevention & control];
Probiotics [adverse effects, *therapeutic use];
Randomized Controlled Trials as Topic [statistics & numerical data];



Medical Subject Headings Check Words

Adolescent;
Child;
Child, Preschool;
Humans;
Infant;



",Probiotics for preventing acute otitis media in children,"Anna M Scott, Justin Clark, Blair Julien, Farhana Islam, Kristian Roos, Keith Grimwood, Paul Little, Chris B Del Mar",Review - Intervention,TRUE,NA,Probiotic compared to placebo for preventing acute otitis media in children,children up to age 18 years,"community, primary care, and secondary care",comparator," Acute otitis media (AOM), or acute middle ear infection, is one of the most frequently occurring childhood diseases, and the most common reason given for prescribing antibiotics in this age group. Guidelines often recommend antibiotics as first‐line treatment for severe AOM. However, antibiotics also lead to antibiotic resistance, so preventing episodes of AOM is an urgent priority.  ", To assess the effects of probiotics to prevent the occurrence and reduce the severity of acute otitis media in children.  ," We searched CENTRAL, PubMed, Embase, and three other databases (October 2018), two trial registers (October 2018), and conducted a backwards and forwards citation analysis (August 2018). We did not apply any language, publication date, or publication status restrictions.  "," We searched CENTRAL, PubMed, Embase, and three other databases (October 2018), two trial registers (October 2018), and conducted a backwards and forwards citation analysis (August 2018). We did not apply any language, publication date, or publication status restrictions.  Selection criteria Randomised controlled trials (RCTs) of children (aged up to 18 years), comparing probiotics with placebo, usual care, or no probiotic.  "," Two review authors independently assessed the eligibility of trials for inclusion and risk of bias of the included trials, and extracted data using pre‐piloted data extraction forms. We analysed dichotomous data as either risk ratio (RR) or odds ratios (OR) and continuous data as mean differences (MD).  "," We included 17 RCTs involving 3488 children, of which 16 RCTs were included in the meta‐analyses. Of the 16 RCTs that reported the mean age of children, mean age overall was 2.4 years; in 4 RCTs the mean age of children participating in the trial was less than 1 year old; in 2 RCTs the mean age was between 1 and 2 years old; and in 10 RCTs the mean age was older than 2 years. Probiotic strains evaluated by the trials varied, with 11 of the included RCTs evaluating Lactobacillus‐containing probiotics, and six RCTs evaluating Streptococcus‐containing probiotics.  The proportion of children (i.e. the number of children in each group) experiencing one or more episodes of AOM during the treatment was lower for those taking probiotics (RR 0.77, 95% confidence interval (CI) 0.63 to 0.93; 16 trials; 2961 participants; number needed to treat for an additional beneficial outcome (NNTB) = 10; moderate‐certainty evidence).  Post hoc subgroup analysis found that among children not prone to otitis media, a lower proportion of children receiving probiotics experienced AOM (RR 0.64, 95% CI 0.49 to 0.84; 11 trials; 2227 participants; NNTB = 9; moderate‐certainty evidence). However, among children who were otitis prone, there was no difference between probiotic and comparator groups (RR 0.97, 95% CI 0.85 to 1.11; 5 trials; 734 participants; high‐certainty evidence). The test for subgroup differences was significant (P = 0.007).  None of the included trials reported on the severity of AOM. The proportion of children experiencing adverse events did not differ between the probiotic and comparator groups (OR 1.54, 95% CI 0.60 to 3.94; 4 trials; 395 participants; low‐certainty evidence).  Probiotics decreased the proportion of children taking antibiotics for any infection (RR 0.66, 95% CI 0.51 to 0.86; 8 trials; 1768 participants; NNTB = 8; moderate‐certainty evidence). Test for subgroup differences (use of antibiotic specifically for AOM, use of antibiotic for infections other than AOM) was not significant.  There was no difference in the mean number of school days lost (MD −0.95, 95% CI −2.47 to 0.57; 5 trials; 1280 participants; moderate‐certainty evidence). There was no difference between groups in the level of compliance in taking the intervention (RR 1.02, 95% CI 0.99 to 1.05; 5 trials; 990 participants).  Probiotics decreased the proportion of children having other infections (RR 0.75, 95% CI 0.65 to 0.87; 11 trials; 3610 participants; NNTB = 12; moderate‐certainty evidence). Test for subgroup differences (acute respiratory infections, gastrointestinal infections) was not significant.  Probiotic strains trialled and their dose, frequency, and duration of administration varied considerably across studies, which likely contributed to the substantial levels of heterogeneity. Sensitivity testing of funnel plots did not reveal publication bias.  "," Probiotics may prevent AOM in children not prone to AOM, but the inconsistency of the subgroup analyses suggests caution in interpreting these results. Probiotics decreased the proportion of children taking antibiotics for any infection. The proportion of children experiencing adverse events did not differ between the probiotic and comparator groups. The optimal strain, duration, frequency, and timing of probiotic administration still needs to be established.   ",1,TRUE,FALSE,5,Proportion of children with AOM: children prone to AOM,RR 0.97 (0.85 to 1.11),734 (5 RCTs),⊕⊕⊕⊕ HIGH,The follow‐up duration ranged from 20 days to 2 years.,RR,734,5,0.85,1.11,RR 0.97,Initializing
https://doi.org/10.1002/14651858.CD012941.pub2,18 June 2019,Intervention,Cochrane Acute Respiratory Infections Group,"Keywords


Medical Subject Headings (MeSH) Keywords

Acute Disease;
Anti‐Bacterial Agents [therapeutic use];
Disease Susceptibility;
Otitis Media [epidemiology, *prevention & control];
Probiotics [adverse effects, *therapeutic use];
Randomized Controlled Trials as Topic [statistics & numerical data];



Medical Subject Headings Check Words

Adolescent;
Child;
Child, Preschool;
Humans;
Infant;



",Probiotics for preventing acute otitis media in children,"Anna M Scott, Justin Clark, Blair Julien, Farhana Islam, Kristian Roos, Keith Grimwood, Paul Little, Chris B Del Mar",Review - Intervention,TRUE,NA,Probiotic compared to placebo for preventing acute otitis media in children,children up to age 18 years,"community, primary care, and secondary care",comparator," Acute otitis media (AOM), or acute middle ear infection, is one of the most frequently occurring childhood diseases, and the most common reason given for prescribing antibiotics in this age group. Guidelines often recommend antibiotics as first‐line treatment for severe AOM. However, antibiotics also lead to antibiotic resistance, so preventing episodes of AOM is an urgent priority.  ", To assess the effects of probiotics to prevent the occurrence and reduce the severity of acute otitis media in children.  ," We searched CENTRAL, PubMed, Embase, and three other databases (October 2018), two trial registers (October 2018), and conducted a backwards and forwards citation analysis (August 2018). We did not apply any language, publication date, or publication status restrictions.  "," We searched CENTRAL, PubMed, Embase, and three other databases (October 2018), two trial registers (October 2018), and conducted a backwards and forwards citation analysis (August 2018). We did not apply any language, publication date, or publication status restrictions.  Selection criteria Randomised controlled trials (RCTs) of children (aged up to 18 years), comparing probiotics with placebo, usual care, or no probiotic.  "," Two review authors independently assessed the eligibility of trials for inclusion and risk of bias of the included trials, and extracted data using pre‐piloted data extraction forms. We analysed dichotomous data as either risk ratio (RR) or odds ratios (OR) and continuous data as mean differences (MD).  "," We included 17 RCTs involving 3488 children, of which 16 RCTs were included in the meta‐analyses. Of the 16 RCTs that reported the mean age of children, mean age overall was 2.4 years; in 4 RCTs the mean age of children participating in the trial was less than 1 year old; in 2 RCTs the mean age was between 1 and 2 years old; and in 10 RCTs the mean age was older than 2 years. Probiotic strains evaluated by the trials varied, with 11 of the included RCTs evaluating Lactobacillus‐containing probiotics, and six RCTs evaluating Streptococcus‐containing probiotics.  The proportion of children (i.e. the number of children in each group) experiencing one or more episodes of AOM during the treatment was lower for those taking probiotics (RR 0.77, 95% confidence interval (CI) 0.63 to 0.93; 16 trials; 2961 participants; number needed to treat for an additional beneficial outcome (NNTB) = 10; moderate‐certainty evidence).  Post hoc subgroup analysis found that among children not prone to otitis media, a lower proportion of children receiving probiotics experienced AOM (RR 0.64, 95% CI 0.49 to 0.84; 11 trials; 2227 participants; NNTB = 9; moderate‐certainty evidence). However, among children who were otitis prone, there was no difference between probiotic and comparator groups (RR 0.97, 95% CI 0.85 to 1.11; 5 trials; 734 participants; high‐certainty evidence). The test for subgroup differences was significant (P = 0.007).  None of the included trials reported on the severity of AOM. The proportion of children experiencing adverse events did not differ between the probiotic and comparator groups (OR 1.54, 95% CI 0.60 to 3.94; 4 trials; 395 participants; low‐certainty evidence).  Probiotics decreased the proportion of children taking antibiotics for any infection (RR 0.66, 95% CI 0.51 to 0.86; 8 trials; 1768 participants; NNTB = 8; moderate‐certainty evidence). Test for subgroup differences (use of antibiotic specifically for AOM, use of antibiotic for infections other than AOM) was not significant.  There was no difference in the mean number of school days lost (MD −0.95, 95% CI −2.47 to 0.57; 5 trials; 1280 participants; moderate‐certainty evidence). There was no difference between groups in the level of compliance in taking the intervention (RR 1.02, 95% CI 0.99 to 1.05; 5 trials; 990 participants).  Probiotics decreased the proportion of children having other infections (RR 0.75, 95% CI 0.65 to 0.87; 11 trials; 3610 participants; NNTB = 12; moderate‐certainty evidence). Test for subgroup differences (acute respiratory infections, gastrointestinal infections) was not significant.  Probiotic strains trialled and their dose, frequency, and duration of administration varied considerably across studies, which likely contributed to the substantial levels of heterogeneity. Sensitivity testing of funnel plots did not reveal publication bias.  "," Probiotics may prevent AOM in children not prone to AOM, but the inconsistency of the subgroup analyses suggests caution in interpreting these results. Probiotics decreased the proportion of children taking antibiotics for any infection. The proportion of children experiencing adverse events did not differ between the probiotic and comparator groups. The optimal strain, duration, frequency, and timing of probiotic administration still needs to be established.   ",1,TRUE,FALSE,6,Proportion of children with AOM: children prone to AOM,RR 0.97 (0.85 to 1.11),734 (5 RCTs),⊕⊕⊕⊕ HIGH,641 per 1000 (561 to 733),RR,734,5,0.85,1.11,RR 0.97,Initializing
https://doi.org/10.1002/14651858.CD012941.pub2,18 June 2019,Intervention,Cochrane Acute Respiratory Infections Group,"Keywords


Medical Subject Headings (MeSH) Keywords

Acute Disease;
Anti‐Bacterial Agents [therapeutic use];
Disease Susceptibility;
Otitis Media [epidemiology, *prevention & control];
Probiotics [adverse effects, *therapeutic use];
Randomized Controlled Trials as Topic [statistics & numerical data];



Medical Subject Headings Check Words

Adolescent;
Child;
Child, Preschool;
Humans;
Infant;



",Probiotics for preventing acute otitis media in children,"Anna M Scott, Justin Clark, Blair Julien, Farhana Islam, Kristian Roos, Keith Grimwood, Paul Little, Chris B Del Mar",Review - Intervention,TRUE,NA,Probiotic compared to placebo for preventing acute otitis media in children,children up to age 18 years,"community, primary care, and secondary care",comparator," Acute otitis media (AOM), or acute middle ear infection, is one of the most frequently occurring childhood diseases, and the most common reason given for prescribing antibiotics in this age group. Guidelines often recommend antibiotics as first‐line treatment for severe AOM. However, antibiotics also lead to antibiotic resistance, so preventing episodes of AOM is an urgent priority.  ", To assess the effects of probiotics to prevent the occurrence and reduce the severity of acute otitis media in children.  ," We searched CENTRAL, PubMed, Embase, and three other databases (October 2018), two trial registers (October 2018), and conducted a backwards and forwards citation analysis (August 2018). We did not apply any language, publication date, or publication status restrictions.  "," We searched CENTRAL, PubMed, Embase, and three other databases (October 2018), two trial registers (October 2018), and conducted a backwards and forwards citation analysis (August 2018). We did not apply any language, publication date, or publication status restrictions.  Selection criteria Randomised controlled trials (RCTs) of children (aged up to 18 years), comparing probiotics with placebo, usual care, or no probiotic.  "," Two review authors independently assessed the eligibility of trials for inclusion and risk of bias of the included trials, and extracted data using pre‐piloted data extraction forms. We analysed dichotomous data as either risk ratio (RR) or odds ratios (OR) and continuous data as mean differences (MD).  "," We included 17 RCTs involving 3488 children, of which 16 RCTs were included in the meta‐analyses. Of the 16 RCTs that reported the mean age of children, mean age overall was 2.4 years; in 4 RCTs the mean age of children participating in the trial was less than 1 year old; in 2 RCTs the mean age was between 1 and 2 years old; and in 10 RCTs the mean age was older than 2 years. Probiotic strains evaluated by the trials varied, with 11 of the included RCTs evaluating Lactobacillus‐containing probiotics, and six RCTs evaluating Streptococcus‐containing probiotics.  The proportion of children (i.e. the number of children in each group) experiencing one or more episodes of AOM during the treatment was lower for those taking probiotics (RR 0.77, 95% confidence interval (CI) 0.63 to 0.93; 16 trials; 2961 participants; number needed to treat for an additional beneficial outcome (NNTB) = 10; moderate‐certainty evidence).  Post hoc subgroup analysis found that among children not prone to otitis media, a lower proportion of children receiving probiotics experienced AOM (RR 0.64, 95% CI 0.49 to 0.84; 11 trials; 2227 participants; NNTB = 9; moderate‐certainty evidence). However, among children who were otitis prone, there was no difference between probiotic and comparator groups (RR 0.97, 95% CI 0.85 to 1.11; 5 trials; 734 participants; high‐certainty evidence). The test for subgroup differences was significant (P = 0.007).  None of the included trials reported on the severity of AOM. The proportion of children experiencing adverse events did not differ between the probiotic and comparator groups (OR 1.54, 95% CI 0.60 to 3.94; 4 trials; 395 participants; low‐certainty evidence).  Probiotics decreased the proportion of children taking antibiotics for any infection (RR 0.66, 95% CI 0.51 to 0.86; 8 trials; 1768 participants; NNTB = 8; moderate‐certainty evidence). Test for subgroup differences (use of antibiotic specifically for AOM, use of antibiotic for infections other than AOM) was not significant.  There was no difference in the mean number of school days lost (MD −0.95, 95% CI −2.47 to 0.57; 5 trials; 1280 participants; moderate‐certainty evidence). There was no difference between groups in the level of compliance in taking the intervention (RR 1.02, 95% CI 0.99 to 1.05; 5 trials; 990 participants).  Probiotics decreased the proportion of children having other infections (RR 0.75, 95% CI 0.65 to 0.87; 11 trials; 3610 participants; NNTB = 12; moderate‐certainty evidence). Test for subgroup differences (acute respiratory infections, gastrointestinal infections) was not significant.  Probiotic strains trialled and their dose, frequency, and duration of administration varied considerably across studies, which likely contributed to the substantial levels of heterogeneity. Sensitivity testing of funnel plots did not reveal publication bias.  "," Probiotics may prevent AOM in children not prone to AOM, but the inconsistency of the subgroup analyses suggests caution in interpreting these results. Probiotics decreased the proportion of children taking antibiotics for any infection. The proportion of children experiencing adverse events did not differ between the probiotic and comparator groups. The optimal strain, duration, frequency, and timing of probiotic administration still needs to be established.   ",1,TRUE,FALSE,7,Severity of AOM,No data,No data,N/A,None of the included studies reported on this outcome.,"NA",NA,4,NA,NA,No ,Initializing
https://doi.org/10.1002/14651858.CD012941.pub2,18 June 2019,Intervention,Cochrane Acute Respiratory Infections Group,"Keywords


Medical Subject Headings (MeSH) Keywords

Acute Disease;
Anti‐Bacterial Agents [therapeutic use];
Disease Susceptibility;
Otitis Media [epidemiology, *prevention & control];
Probiotics [adverse effects, *therapeutic use];
Randomized Controlled Trials as Topic [statistics & numerical data];



Medical Subject Headings Check Words

Adolescent;
Child;
Child, Preschool;
Humans;
Infant;



",Probiotics for preventing acute otitis media in children,"Anna M Scott, Justin Clark, Blair Julien, Farhana Islam, Kristian Roos, Keith Grimwood, Paul Little, Chris B Del Mar",Review - Intervention,TRUE,NA,Probiotic compared to placebo for preventing acute otitis media in children,children up to age 18 years,"community, primary care, and secondary care",comparator," Acute otitis media (AOM), or acute middle ear infection, is one of the most frequently occurring childhood diseases, and the most common reason given for prescribing antibiotics in this age group. Guidelines often recommend antibiotics as first‐line treatment for severe AOM. However, antibiotics also lead to antibiotic resistance, so preventing episodes of AOM is an urgent priority.  ", To assess the effects of probiotics to prevent the occurrence and reduce the severity of acute otitis media in children.  ," We searched CENTRAL, PubMed, Embase, and three other databases (October 2018), two trial registers (October 2018), and conducted a backwards and forwards citation analysis (August 2018). We did not apply any language, publication date, or publication status restrictions.  "," We searched CENTRAL, PubMed, Embase, and three other databases (October 2018), two trial registers (October 2018), and conducted a backwards and forwards citation analysis (August 2018). We did not apply any language, publication date, or publication status restrictions.  Selection criteria Randomised controlled trials (RCTs) of children (aged up to 18 years), comparing probiotics with placebo, usual care, or no probiotic.  "," Two review authors independently assessed the eligibility of trials for inclusion and risk of bias of the included trials, and extracted data using pre‐piloted data extraction forms. We analysed dichotomous data as either risk ratio (RR) or odds ratios (OR) and continuous data as mean differences (MD).  "," We included 17 RCTs involving 3488 children, of which 16 RCTs were included in the meta‐analyses. Of the 16 RCTs that reported the mean age of children, mean age overall was 2.4 years; in 4 RCTs the mean age of children participating in the trial was less than 1 year old; in 2 RCTs the mean age was between 1 and 2 years old; and in 10 RCTs the mean age was older than 2 years. Probiotic strains evaluated by the trials varied, with 11 of the included RCTs evaluating Lactobacillus‐containing probiotics, and six RCTs evaluating Streptococcus‐containing probiotics.  The proportion of children (i.e. the number of children in each group) experiencing one or more episodes of AOM during the treatment was lower for those taking probiotics (RR 0.77, 95% confidence interval (CI) 0.63 to 0.93; 16 trials; 2961 participants; number needed to treat for an additional beneficial outcome (NNTB) = 10; moderate‐certainty evidence).  Post hoc subgroup analysis found that among children not prone to otitis media, a lower proportion of children receiving probiotics experienced AOM (RR 0.64, 95% CI 0.49 to 0.84; 11 trials; 2227 participants; NNTB = 9; moderate‐certainty evidence). However, among children who were otitis prone, there was no difference between probiotic and comparator groups (RR 0.97, 95% CI 0.85 to 1.11; 5 trials; 734 participants; high‐certainty evidence). The test for subgroup differences was significant (P = 0.007).  None of the included trials reported on the severity of AOM. The proportion of children experiencing adverse events did not differ between the probiotic and comparator groups (OR 1.54, 95% CI 0.60 to 3.94; 4 trials; 395 participants; low‐certainty evidence).  Probiotics decreased the proportion of children taking antibiotics for any infection (RR 0.66, 95% CI 0.51 to 0.86; 8 trials; 1768 participants; NNTB = 8; moderate‐certainty evidence). Test for subgroup differences (use of antibiotic specifically for AOM, use of antibiotic for infections other than AOM) was not significant.  There was no difference in the mean number of school days lost (MD −0.95, 95% CI −2.47 to 0.57; 5 trials; 1280 participants; moderate‐certainty evidence). There was no difference between groups in the level of compliance in taking the intervention (RR 1.02, 95% CI 0.99 to 1.05; 5 trials; 990 participants).  Probiotics decreased the proportion of children having other infections (RR 0.75, 95% CI 0.65 to 0.87; 11 trials; 3610 participants; NNTB = 12; moderate‐certainty evidence). Test for subgroup differences (acute respiratory infections, gastrointestinal infections) was not significant.  Probiotic strains trialled and their dose, frequency, and duration of administration varied considerably across studies, which likely contributed to the substantial levels of heterogeneity. Sensitivity testing of funnel plots did not reveal publication bias.  "," Probiotics may prevent AOM in children not prone to AOM, but the inconsistency of the subgroup analyses suggests caution in interpreting these results. Probiotics decreased the proportion of children taking antibiotics for any infection. The proportion of children experiencing adverse events did not differ between the probiotic and comparator groups. The optimal strain, duration, frequency, and timing of probiotic administration still needs to be established.   ",1,TRUE,FALSE,8,Adverse events,OR 1.54 (0.60 to 3.94),395 (4 RCTs),⊕⊕⊝⊝ LOW3,The follow‐up duration ranged from 20 days to 2 years.,OR,395,4,0.60,3.94,OR 1.54,Initializing
https://doi.org/10.1002/14651858.CD012941.pub2,18 June 2019,Intervention,Cochrane Acute Respiratory Infections Group,"Keywords


Medical Subject Headings (MeSH) Keywords

Acute Disease;
Anti‐Bacterial Agents [therapeutic use];
Disease Susceptibility;
Otitis Media [epidemiology, *prevention & control];
Probiotics [adverse effects, *therapeutic use];
Randomized Controlled Trials as Topic [statistics & numerical data];



Medical Subject Headings Check Words

Adolescent;
Child;
Child, Preschool;
Humans;
Infant;



",Probiotics for preventing acute otitis media in children,"Anna M Scott, Justin Clark, Blair Julien, Farhana Islam, Kristian Roos, Keith Grimwood, Paul Little, Chris B Del Mar",Review - Intervention,TRUE,NA,Probiotic compared to placebo for preventing acute otitis media in children,children up to age 18 years,"community, primary care, and secondary care",comparator," Acute otitis media (AOM), or acute middle ear infection, is one of the most frequently occurring childhood diseases, and the most common reason given for prescribing antibiotics in this age group. Guidelines often recommend antibiotics as first‐line treatment for severe AOM. However, antibiotics also lead to antibiotic resistance, so preventing episodes of AOM is an urgent priority.  ", To assess the effects of probiotics to prevent the occurrence and reduce the severity of acute otitis media in children.  ," We searched CENTRAL, PubMed, Embase, and three other databases (October 2018), two trial registers (October 2018), and conducted a backwards and forwards citation analysis (August 2018). We did not apply any language, publication date, or publication status restrictions.  "," We searched CENTRAL, PubMed, Embase, and three other databases (October 2018), two trial registers (October 2018), and conducted a backwards and forwards citation analysis (August 2018). We did not apply any language, publication date, or publication status restrictions.  Selection criteria Randomised controlled trials (RCTs) of children (aged up to 18 years), comparing probiotics with placebo, usual care, or no probiotic.  "," Two review authors independently assessed the eligibility of trials for inclusion and risk of bias of the included trials, and extracted data using pre‐piloted data extraction forms. We analysed dichotomous data as either risk ratio (RR) or odds ratios (OR) and continuous data as mean differences (MD).  "," We included 17 RCTs involving 3488 children, of which 16 RCTs were included in the meta‐analyses. Of the 16 RCTs that reported the mean age of children, mean age overall was 2.4 years; in 4 RCTs the mean age of children participating in the trial was less than 1 year old; in 2 RCTs the mean age was between 1 and 2 years old; and in 10 RCTs the mean age was older than 2 years. Probiotic strains evaluated by the trials varied, with 11 of the included RCTs evaluating Lactobacillus‐containing probiotics, and six RCTs evaluating Streptococcus‐containing probiotics.  The proportion of children (i.e. the number of children in each group) experiencing one or more episodes of AOM during the treatment was lower for those taking probiotics (RR 0.77, 95% confidence interval (CI) 0.63 to 0.93; 16 trials; 2961 participants; number needed to treat for an additional beneficial outcome (NNTB) = 10; moderate‐certainty evidence).  Post hoc subgroup analysis found that among children not prone to otitis media, a lower proportion of children receiving probiotics experienced AOM (RR 0.64, 95% CI 0.49 to 0.84; 11 trials; 2227 participants; NNTB = 9; moderate‐certainty evidence). However, among children who were otitis prone, there was no difference between probiotic and comparator groups (RR 0.97, 95% CI 0.85 to 1.11; 5 trials; 734 participants; high‐certainty evidence). The test for subgroup differences was significant (P = 0.007).  None of the included trials reported on the severity of AOM. The proportion of children experiencing adverse events did not differ between the probiotic and comparator groups (OR 1.54, 95% CI 0.60 to 3.94; 4 trials; 395 participants; low‐certainty evidence).  Probiotics decreased the proportion of children taking antibiotics for any infection (RR 0.66, 95% CI 0.51 to 0.86; 8 trials; 1768 participants; NNTB = 8; moderate‐certainty evidence). Test for subgroup differences (use of antibiotic specifically for AOM, use of antibiotic for infections other than AOM) was not significant.  There was no difference in the mean number of school days lost (MD −0.95, 95% CI −2.47 to 0.57; 5 trials; 1280 participants; moderate‐certainty evidence). There was no difference between groups in the level of compliance in taking the intervention (RR 1.02, 95% CI 0.99 to 1.05; 5 trials; 990 participants).  Probiotics decreased the proportion of children having other infections (RR 0.75, 95% CI 0.65 to 0.87; 11 trials; 3610 participants; NNTB = 12; moderate‐certainty evidence). Test for subgroup differences (acute respiratory infections, gastrointestinal infections) was not significant.  Probiotic strains trialled and their dose, frequency, and duration of administration varied considerably across studies, which likely contributed to the substantial levels of heterogeneity. Sensitivity testing of funnel plots did not reveal publication bias.  "," Probiotics may prevent AOM in children not prone to AOM, but the inconsistency of the subgroup analyses suggests caution in interpreting these results. Probiotics decreased the proportion of children taking antibiotics for any infection. The proportion of children experiencing adverse events did not differ between the probiotic and comparator groups. The optimal strain, duration, frequency, and timing of probiotic administration still needs to be established.   ",1,TRUE,FALSE,9,Adverse events,OR 1.54 (0.60 to 3.94),395 (4 RCTs),⊕⊕⊝⊝ LOW3,260 per 1000 (121 to 474),OR,395,5,0.60,3.94,OR 1.54,Initializing
https://doi.org/10.1002/14651858.CD012941.pub2,18 June 2019,Intervention,Cochrane Acute Respiratory Infections Group,"Keywords


Medical Subject Headings (MeSH) Keywords

Acute Disease;
Anti‐Bacterial Agents [therapeutic use];
Disease Susceptibility;
Otitis Media [epidemiology, *prevention & control];
Probiotics [adverse effects, *therapeutic use];
Randomized Controlled Trials as Topic [statistics & numerical data];



Medical Subject Headings Check Words

Adolescent;
Child;
Child, Preschool;
Humans;
Infant;



",Probiotics for preventing acute otitis media in children,"Anna M Scott, Justin Clark, Blair Julien, Farhana Islam, Kristian Roos, Keith Grimwood, Paul Little, Chris B Del Mar",Review - Intervention,TRUE,NA,Probiotic compared to placebo for preventing acute otitis media in children,children up to age 18 years,"community, primary care, and secondary care",comparator," Acute otitis media (AOM), or acute middle ear infection, is one of the most frequently occurring childhood diseases, and the most common reason given for prescribing antibiotics in this age group. Guidelines often recommend antibiotics as first‐line treatment for severe AOM. However, antibiotics also lead to antibiotic resistance, so preventing episodes of AOM is an urgent priority.  ", To assess the effects of probiotics to prevent the occurrence and reduce the severity of acute otitis media in children.  ," We searched CENTRAL, PubMed, Embase, and three other databases (October 2018), two trial registers (October 2018), and conducted a backwards and forwards citation analysis (August 2018). We did not apply any language, publication date, or publication status restrictions.  "," We searched CENTRAL, PubMed, Embase, and three other databases (October 2018), two trial registers (October 2018), and conducted a backwards and forwards citation analysis (August 2018). We did not apply any language, publication date, or publication status restrictions.  Selection criteria Randomised controlled trials (RCTs) of children (aged up to 18 years), comparing probiotics with placebo, usual care, or no probiotic.  "," Two review authors independently assessed the eligibility of trials for inclusion and risk of bias of the included trials, and extracted data using pre‐piloted data extraction forms. We analysed dichotomous data as either risk ratio (RR) or odds ratios (OR) and continuous data as mean differences (MD).  "," We included 17 RCTs involving 3488 children, of which 16 RCTs were included in the meta‐analyses. Of the 16 RCTs that reported the mean age of children, mean age overall was 2.4 years; in 4 RCTs the mean age of children participating in the trial was less than 1 year old; in 2 RCTs the mean age was between 1 and 2 years old; and in 10 RCTs the mean age was older than 2 years. Probiotic strains evaluated by the trials varied, with 11 of the included RCTs evaluating Lactobacillus‐containing probiotics, and six RCTs evaluating Streptococcus‐containing probiotics.  The proportion of children (i.e. the number of children in each group) experiencing one or more episodes of AOM during the treatment was lower for those taking probiotics (RR 0.77, 95% confidence interval (CI) 0.63 to 0.93; 16 trials; 2961 participants; number needed to treat for an additional beneficial outcome (NNTB) = 10; moderate‐certainty evidence).  Post hoc subgroup analysis found that among children not prone to otitis media, a lower proportion of children receiving probiotics experienced AOM (RR 0.64, 95% CI 0.49 to 0.84; 11 trials; 2227 participants; NNTB = 9; moderate‐certainty evidence). However, among children who were otitis prone, there was no difference between probiotic and comparator groups (RR 0.97, 95% CI 0.85 to 1.11; 5 trials; 734 participants; high‐certainty evidence). The test for subgroup differences was significant (P = 0.007).  None of the included trials reported on the severity of AOM. The proportion of children experiencing adverse events did not differ between the probiotic and comparator groups (OR 1.54, 95% CI 0.60 to 3.94; 4 trials; 395 participants; low‐certainty evidence).  Probiotics decreased the proportion of children taking antibiotics for any infection (RR 0.66, 95% CI 0.51 to 0.86; 8 trials; 1768 participants; NNTB = 8; moderate‐certainty evidence). Test for subgroup differences (use of antibiotic specifically for AOM, use of antibiotic for infections other than AOM) was not significant.  There was no difference in the mean number of school days lost (MD −0.95, 95% CI −2.47 to 0.57; 5 trials; 1280 participants; moderate‐certainty evidence). There was no difference between groups in the level of compliance in taking the intervention (RR 1.02, 95% CI 0.99 to 1.05; 5 trials; 990 participants).  Probiotics decreased the proportion of children having other infections (RR 0.75, 95% CI 0.65 to 0.87; 11 trials; 3610 participants; NNTB = 12; moderate‐certainty evidence). Test for subgroup differences (acute respiratory infections, gastrointestinal infections) was not significant.  Probiotic strains trialled and their dose, frequency, and duration of administration varied considerably across studies, which likely contributed to the substantial levels of heterogeneity. Sensitivity testing of funnel plots did not reveal publication bias.  "," Probiotics may prevent AOM in children not prone to AOM, but the inconsistency of the subgroup analyses suggests caution in interpreting these results. Probiotics decreased the proportion of children taking antibiotics for any infection. The proportion of children experiencing adverse events did not differ between the probiotic and comparator groups. The optimal strain, duration, frequency, and timing of probiotic administration still needs to be established.   ",1,TRUE,FALSE,10,Time off school for child,‐‐,1280 (5 RCTs),⊕⊕⊕⊝ MODERATE4,The follow‐up duration ranged from 20 days to 2 years. The median of trial means for the probiotic group was 4.45 days of absence; the median of trial means for the comparator group was 5.8 days of absence.,MD,1280,8,NA,NA,NA,Initializing
https://doi.org/10.1002/14651858.CD012941.pub2,18 June 2019,Intervention,Cochrane Acute Respiratory Infections Group,"Keywords


Medical Subject Headings (MeSH) Keywords

Acute Disease;
Anti‐Bacterial Agents [therapeutic use];
Disease Susceptibility;
Otitis Media [epidemiology, *prevention & control];
Probiotics [adverse effects, *therapeutic use];
Randomized Controlled Trials as Topic [statistics & numerical data];



Medical Subject Headings Check Words

Adolescent;
Child;
Child, Preschool;
Humans;
Infant;



",Probiotics for preventing acute otitis media in children,"Anna M Scott, Justin Clark, Blair Julien, Farhana Islam, Kristian Roos, Keith Grimwood, Paul Little, Chris B Del Mar",Review - Intervention,TRUE,NA,Probiotic compared to placebo for preventing acute otitis media in children,children up to age 18 years,"community, primary care, and secondary care",comparator," Acute otitis media (AOM), or acute middle ear infection, is one of the most frequently occurring childhood diseases, and the most common reason given for prescribing antibiotics in this age group. Guidelines often recommend antibiotics as first‐line treatment for severe AOM. However, antibiotics also lead to antibiotic resistance, so preventing episodes of AOM is an urgent priority.  ", To assess the effects of probiotics to prevent the occurrence and reduce the severity of acute otitis media in children.  ," We searched CENTRAL, PubMed, Embase, and three other databases (October 2018), two trial registers (October 2018), and conducted a backwards and forwards citation analysis (August 2018). We did not apply any language, publication date, or publication status restrictions.  "," We searched CENTRAL, PubMed, Embase, and three other databases (October 2018), two trial registers (October 2018), and conducted a backwards and forwards citation analysis (August 2018). We did not apply any language, publication date, or publication status restrictions.  Selection criteria Randomised controlled trials (RCTs) of children (aged up to 18 years), comparing probiotics with placebo, usual care, or no probiotic.  "," Two review authors independently assessed the eligibility of trials for inclusion and risk of bias of the included trials, and extracted data using pre‐piloted data extraction forms. We analysed dichotomous data as either risk ratio (RR) or odds ratios (OR) and continuous data as mean differences (MD).  "," We included 17 RCTs involving 3488 children, of which 16 RCTs were included in the meta‐analyses. Of the 16 RCTs that reported the mean age of children, mean age overall was 2.4 years; in 4 RCTs the mean age of children participating in the trial was less than 1 year old; in 2 RCTs the mean age was between 1 and 2 years old; and in 10 RCTs the mean age was older than 2 years. Probiotic strains evaluated by the trials varied, with 11 of the included RCTs evaluating Lactobacillus‐containing probiotics, and six RCTs evaluating Streptococcus‐containing probiotics.  The proportion of children (i.e. the number of children in each group) experiencing one or more episodes of AOM during the treatment was lower for those taking probiotics (RR 0.77, 95% confidence interval (CI) 0.63 to 0.93; 16 trials; 2961 participants; number needed to treat for an additional beneficial outcome (NNTB) = 10; moderate‐certainty evidence).  Post hoc subgroup analysis found that among children not prone to otitis media, a lower proportion of children receiving probiotics experienced AOM (RR 0.64, 95% CI 0.49 to 0.84; 11 trials; 2227 participants; NNTB = 9; moderate‐certainty evidence). However, among children who were otitis prone, there was no difference between probiotic and comparator groups (RR 0.97, 95% CI 0.85 to 1.11; 5 trials; 734 participants; high‐certainty evidence). The test for subgroup differences was significant (P = 0.007).  None of the included trials reported on the severity of AOM. The proportion of children experiencing adverse events did not differ between the probiotic and comparator groups (OR 1.54, 95% CI 0.60 to 3.94; 4 trials; 395 participants; low‐certainty evidence).  Probiotics decreased the proportion of children taking antibiotics for any infection (RR 0.66, 95% CI 0.51 to 0.86; 8 trials; 1768 participants; NNTB = 8; moderate‐certainty evidence). Test for subgroup differences (use of antibiotic specifically for AOM, use of antibiotic for infections other than AOM) was not significant.  There was no difference in the mean number of school days lost (MD −0.95, 95% CI −2.47 to 0.57; 5 trials; 1280 participants; moderate‐certainty evidence). There was no difference between groups in the level of compliance in taking the intervention (RR 1.02, 95% CI 0.99 to 1.05; 5 trials; 990 participants).  Probiotics decreased the proportion of children having other infections (RR 0.75, 95% CI 0.65 to 0.87; 11 trials; 3610 participants; NNTB = 12; moderate‐certainty evidence). Test for subgroup differences (acute respiratory infections, gastrointestinal infections) was not significant.  Probiotic strains trialled and their dose, frequency, and duration of administration varied considerably across studies, which likely contributed to the substantial levels of heterogeneity. Sensitivity testing of funnel plots did not reveal publication bias.  "," Probiotics may prevent AOM in children not prone to AOM, but the inconsistency of the subgroup analyses suggests caution in interpreting these results. Probiotics decreased the proportion of children taking antibiotics for any infection. The proportion of children experiencing adverse events did not differ between the probiotic and comparator groups. The optimal strain, duration, frequency, and timing of probiotic administration still needs to be established.   ",1,TRUE,FALSE,11,Difference in the use of antibiotics,RR 0.66 (0.51 to 0.86),1768 (8 RCTs),⊕⊕⊕⊝ MODERATE5,The follow‐up duration ranged from 20 days to 2 years.,RR,1768,8,0.51,0.86,RR 0.66,Initializing
https://doi.org/10.1002/14651858.CD012941.pub2,18 June 2019,Intervention,Cochrane Acute Respiratory Infections Group,"Keywords


Medical Subject Headings (MeSH) Keywords

Acute Disease;
Anti‐Bacterial Agents [therapeutic use];
Disease Susceptibility;
Otitis Media [epidemiology, *prevention & control];
Probiotics [adverse effects, *therapeutic use];
Randomized Controlled Trials as Topic [statistics & numerical data];



Medical Subject Headings Check Words

Adolescent;
Child;
Child, Preschool;
Humans;
Infant;



",Probiotics for preventing acute otitis media in children,"Anna M Scott, Justin Clark, Blair Julien, Farhana Islam, Kristian Roos, Keith Grimwood, Paul Little, Chris B Del Mar",Review - Intervention,TRUE,NA,Probiotic compared to placebo for preventing acute otitis media in children,children up to age 18 years,"community, primary care, and secondary care",comparator," Acute otitis media (AOM), or acute middle ear infection, is one of the most frequently occurring childhood diseases, and the most common reason given for prescribing antibiotics in this age group. Guidelines often recommend antibiotics as first‐line treatment for severe AOM. However, antibiotics also lead to antibiotic resistance, so preventing episodes of AOM is an urgent priority.  ", To assess the effects of probiotics to prevent the occurrence and reduce the severity of acute otitis media in children.  ," We searched CENTRAL, PubMed, Embase, and three other databases (October 2018), two trial registers (October 2018), and conducted a backwards and forwards citation analysis (August 2018). We did not apply any language, publication date, or publication status restrictions.  "," We searched CENTRAL, PubMed, Embase, and three other databases (October 2018), two trial registers (October 2018), and conducted a backwards and forwards citation analysis (August 2018). We did not apply any language, publication date, or publication status restrictions.  Selection criteria Randomised controlled trials (RCTs) of children (aged up to 18 years), comparing probiotics with placebo, usual care, or no probiotic.  "," Two review authors independently assessed the eligibility of trials for inclusion and risk of bias of the included trials, and extracted data using pre‐piloted data extraction forms. We analysed dichotomous data as either risk ratio (RR) or odds ratios (OR) and continuous data as mean differences (MD).  "," We included 17 RCTs involving 3488 children, of which 16 RCTs were included in the meta‐analyses. Of the 16 RCTs that reported the mean age of children, mean age overall was 2.4 years; in 4 RCTs the mean age of children participating in the trial was less than 1 year old; in 2 RCTs the mean age was between 1 and 2 years old; and in 10 RCTs the mean age was older than 2 years. Probiotic strains evaluated by the trials varied, with 11 of the included RCTs evaluating Lactobacillus‐containing probiotics, and six RCTs evaluating Streptococcus‐containing probiotics.  The proportion of children (i.e. the number of children in each group) experiencing one or more episodes of AOM during the treatment was lower for those taking probiotics (RR 0.77, 95% confidence interval (CI) 0.63 to 0.93; 16 trials; 2961 participants; number needed to treat for an additional beneficial outcome (NNTB) = 10; moderate‐certainty evidence).  Post hoc subgroup analysis found that among children not prone to otitis media, a lower proportion of children receiving probiotics experienced AOM (RR 0.64, 95% CI 0.49 to 0.84; 11 trials; 2227 participants; NNTB = 9; moderate‐certainty evidence). However, among children who were otitis prone, there was no difference between probiotic and comparator groups (RR 0.97, 95% CI 0.85 to 1.11; 5 trials; 734 participants; high‐certainty evidence). The test for subgroup differences was significant (P = 0.007).  None of the included trials reported on the severity of AOM. The proportion of children experiencing adverse events did not differ between the probiotic and comparator groups (OR 1.54, 95% CI 0.60 to 3.94; 4 trials; 395 participants; low‐certainty evidence).  Probiotics decreased the proportion of children taking antibiotics for any infection (RR 0.66, 95% CI 0.51 to 0.86; 8 trials; 1768 participants; NNTB = 8; moderate‐certainty evidence). Test for subgroup differences (use of antibiotic specifically for AOM, use of antibiotic for infections other than AOM) was not significant.  There was no difference in the mean number of school days lost (MD −0.95, 95% CI −2.47 to 0.57; 5 trials; 1280 participants; moderate‐certainty evidence). There was no difference between groups in the level of compliance in taking the intervention (RR 1.02, 95% CI 0.99 to 1.05; 5 trials; 990 participants).  Probiotics decreased the proportion of children having other infections (RR 0.75, 95% CI 0.65 to 0.87; 11 trials; 3610 participants; NNTB = 12; moderate‐certainty evidence). Test for subgroup differences (acute respiratory infections, gastrointestinal infections) was not significant.  Probiotic strains trialled and their dose, frequency, and duration of administration varied considerably across studies, which likely contributed to the substantial levels of heterogeneity. Sensitivity testing of funnel plots did not reveal publication bias.  "," Probiotics may prevent AOM in children not prone to AOM, but the inconsistency of the subgroup analyses suggests caution in interpreting these results. Probiotics decreased the proportion of children taking antibiotics for any infection. The proportion of children experiencing adverse events did not differ between the probiotic and comparator groups. The optimal strain, duration, frequency, and timing of probiotic administration still needs to be established.   ",1,TRUE,FALSE,12,Difference in the use of antibiotics,RR 0.66 (0.51 to 0.86),1768 (8 RCTs),⊕⊕⊕⊝ MODERATE5,262 per 1000 (203 to 342),RR,1768,11,0.51,0.86,RR 0.66,Initializing
https://doi.org/10.1002/14651858.CD012941.pub2,18 June 2019,Intervention,Cochrane Acute Respiratory Infections Group,"Keywords


Medical Subject Headings (MeSH) Keywords

Acute Disease;
Anti‐Bacterial Agents [therapeutic use];
Disease Susceptibility;
Otitis Media [epidemiology, *prevention & control];
Probiotics [adverse effects, *therapeutic use];
Randomized Controlled Trials as Topic [statistics & numerical data];



Medical Subject Headings Check Words

Adolescent;
Child;
Child, Preschool;
Humans;
Infant;



",Probiotics for preventing acute otitis media in children,"Anna M Scott, Justin Clark, Blair Julien, Farhana Islam, Kristian Roos, Keith Grimwood, Paul Little, Chris B Del Mar",Review - Intervention,TRUE,NA,Probiotic compared to placebo for preventing acute otitis media in children,children up to age 18 years,"community, primary care, and secondary care",comparator," Acute otitis media (AOM), or acute middle ear infection, is one of the most frequently occurring childhood diseases, and the most common reason given for prescribing antibiotics in this age group. Guidelines often recommend antibiotics as first‐line treatment for severe AOM. However, antibiotics also lead to antibiotic resistance, so preventing episodes of AOM is an urgent priority.  ", To assess the effects of probiotics to prevent the occurrence and reduce the severity of acute otitis media in children.  ," We searched CENTRAL, PubMed, Embase, and three other databases (October 2018), two trial registers (October 2018), and conducted a backwards and forwards citation analysis (August 2018). We did not apply any language, publication date, or publication status restrictions.  "," We searched CENTRAL, PubMed, Embase, and three other databases (October 2018), two trial registers (October 2018), and conducted a backwards and forwards citation analysis (August 2018). We did not apply any language, publication date, or publication status restrictions.  Selection criteria Randomised controlled trials (RCTs) of children (aged up to 18 years), comparing probiotics with placebo, usual care, or no probiotic.  "," Two review authors independently assessed the eligibility of trials for inclusion and risk of bias of the included trials, and extracted data using pre‐piloted data extraction forms. We analysed dichotomous data as either risk ratio (RR) or odds ratios (OR) and continuous data as mean differences (MD).  "," We included 17 RCTs involving 3488 children, of which 16 RCTs were included in the meta‐analyses. Of the 16 RCTs that reported the mean age of children, mean age overall was 2.4 years; in 4 RCTs the mean age of children participating in the trial was less than 1 year old; in 2 RCTs the mean age was between 1 and 2 years old; and in 10 RCTs the mean age was older than 2 years. Probiotic strains evaluated by the trials varied, with 11 of the included RCTs evaluating Lactobacillus‐containing probiotics, and six RCTs evaluating Streptococcus‐containing probiotics.  The proportion of children (i.e. the number of children in each group) experiencing one or more episodes of AOM during the treatment was lower for those taking probiotics (RR 0.77, 95% confidence interval (CI) 0.63 to 0.93; 16 trials; 2961 participants; number needed to treat for an additional beneficial outcome (NNTB) = 10; moderate‐certainty evidence).  Post hoc subgroup analysis found that among children not prone to otitis media, a lower proportion of children receiving probiotics experienced AOM (RR 0.64, 95% CI 0.49 to 0.84; 11 trials; 2227 participants; NNTB = 9; moderate‐certainty evidence). However, among children who were otitis prone, there was no difference between probiotic and comparator groups (RR 0.97, 95% CI 0.85 to 1.11; 5 trials; 734 participants; high‐certainty evidence). The test for subgroup differences was significant (P = 0.007).  None of the included trials reported on the severity of AOM. The proportion of children experiencing adverse events did not differ between the probiotic and comparator groups (OR 1.54, 95% CI 0.60 to 3.94; 4 trials; 395 participants; low‐certainty evidence).  Probiotics decreased the proportion of children taking antibiotics for any infection (RR 0.66, 95% CI 0.51 to 0.86; 8 trials; 1768 participants; NNTB = 8; moderate‐certainty evidence). Test for subgroup differences (use of antibiotic specifically for AOM, use of antibiotic for infections other than AOM) was not significant.  There was no difference in the mean number of school days lost (MD −0.95, 95% CI −2.47 to 0.57; 5 trials; 1280 participants; moderate‐certainty evidence). There was no difference between groups in the level of compliance in taking the intervention (RR 1.02, 95% CI 0.99 to 1.05; 5 trials; 990 participants).  Probiotics decreased the proportion of children having other infections (RR 0.75, 95% CI 0.65 to 0.87; 11 trials; 3610 participants; NNTB = 12; moderate‐certainty evidence). Test for subgroup differences (acute respiratory infections, gastrointestinal infections) was not significant.  Probiotic strains trialled and their dose, frequency, and duration of administration varied considerably across studies, which likely contributed to the substantial levels of heterogeneity. Sensitivity testing of funnel plots did not reveal publication bias.  "," Probiotics may prevent AOM in children not prone to AOM, but the inconsistency of the subgroup analyses suggests caution in interpreting these results. Probiotics decreased the proportion of children taking antibiotics for any infection. The proportion of children experiencing adverse events did not differ between the probiotic and comparator groups. The optimal strain, duration, frequency, and timing of probiotic administration still needs to be established.   ",1,TRUE,FALSE,13,Difference in proportion of children with other infections,RR 0.75 (0.65 to 0.87),3610 (11 RCTs),⊕⊕⊕⊝ MODERATE6,The follow‐up duration ranged from 20 days to 2 years.,RR,3610,11,0.65,0.87,RR 0.75,Initializing
https://doi.org/10.1002/14651858.CD012941.pub2,18 June 2019,Intervention,Cochrane Acute Respiratory Infections Group,"Keywords


Medical Subject Headings (MeSH) Keywords

Acute Disease;
Anti‐Bacterial Agents [therapeutic use];
Disease Susceptibility;
Otitis Media [epidemiology, *prevention & control];
Probiotics [adverse effects, *therapeutic use];
Randomized Controlled Trials as Topic [statistics & numerical data];



Medical Subject Headings Check Words

Adolescent;
Child;
Child, Preschool;
Humans;
Infant;



",Probiotics for preventing acute otitis media in children,"Anna M Scott, Justin Clark, Blair Julien, Farhana Islam, Kristian Roos, Keith Grimwood, Paul Little, Chris B Del Mar",Review - Intervention,TRUE,NA,Probiotic compared to placebo for preventing acute otitis media in children,children up to age 18 years,"community, primary care, and secondary care",comparator," Acute otitis media (AOM), or acute middle ear infection, is one of the most frequently occurring childhood diseases, and the most common reason given for prescribing antibiotics in this age group. Guidelines often recommend antibiotics as first‐line treatment for severe AOM. However, antibiotics also lead to antibiotic resistance, so preventing episodes of AOM is an urgent priority.  ", To assess the effects of probiotics to prevent the occurrence and reduce the severity of acute otitis media in children.  ," We searched CENTRAL, PubMed, Embase, and three other databases (October 2018), two trial registers (October 2018), and conducted a backwards and forwards citation analysis (August 2018). We did not apply any language, publication date, or publication status restrictions.  "," We searched CENTRAL, PubMed, Embase, and three other databases (October 2018), two trial registers (October 2018), and conducted a backwards and forwards citation analysis (August 2018). We did not apply any language, publication date, or publication status restrictions.  Selection criteria Randomised controlled trials (RCTs) of children (aged up to 18 years), comparing probiotics with placebo, usual care, or no probiotic.  "," Two review authors independently assessed the eligibility of trials for inclusion and risk of bias of the included trials, and extracted data using pre‐piloted data extraction forms. We analysed dichotomous data as either risk ratio (RR) or odds ratios (OR) and continuous data as mean differences (MD).  "," We included 17 RCTs involving 3488 children, of which 16 RCTs were included in the meta‐analyses. Of the 16 RCTs that reported the mean age of children, mean age overall was 2.4 years; in 4 RCTs the mean age of children participating in the trial was less than 1 year old; in 2 RCTs the mean age was between 1 and 2 years old; and in 10 RCTs the mean age was older than 2 years. Probiotic strains evaluated by the trials varied, with 11 of the included RCTs evaluating Lactobacillus‐containing probiotics, and six RCTs evaluating Streptococcus‐containing probiotics.  The proportion of children (i.e. the number of children in each group) experiencing one or more episodes of AOM during the treatment was lower for those taking probiotics (RR 0.77, 95% confidence interval (CI) 0.63 to 0.93; 16 trials; 2961 participants; number needed to treat for an additional beneficial outcome (NNTB) = 10; moderate‐certainty evidence).  Post hoc subgroup analysis found that among children not prone to otitis media, a lower proportion of children receiving probiotics experienced AOM (RR 0.64, 95% CI 0.49 to 0.84; 11 trials; 2227 participants; NNTB = 9; moderate‐certainty evidence). However, among children who were otitis prone, there was no difference between probiotic and comparator groups (RR 0.97, 95% CI 0.85 to 1.11; 5 trials; 734 participants; high‐certainty evidence). The test for subgroup differences was significant (P = 0.007).  None of the included trials reported on the severity of AOM. The proportion of children experiencing adverse events did not differ between the probiotic and comparator groups (OR 1.54, 95% CI 0.60 to 3.94; 4 trials; 395 participants; low‐certainty evidence).  Probiotics decreased the proportion of children taking antibiotics for any infection (RR 0.66, 95% CI 0.51 to 0.86; 8 trials; 1768 participants; NNTB = 8; moderate‐certainty evidence). Test for subgroup differences (use of antibiotic specifically for AOM, use of antibiotic for infections other than AOM) was not significant.  There was no difference in the mean number of school days lost (MD −0.95, 95% CI −2.47 to 0.57; 5 trials; 1280 participants; moderate‐certainty evidence). There was no difference between groups in the level of compliance in taking the intervention (RR 1.02, 95% CI 0.99 to 1.05; 5 trials; 990 participants).  Probiotics decreased the proportion of children having other infections (RR 0.75, 95% CI 0.65 to 0.87; 11 trials; 3610 participants; NNTB = 12; moderate‐certainty evidence). Test for subgroup differences (acute respiratory infections, gastrointestinal infections) was not significant.  Probiotic strains trialled and their dose, frequency, and duration of administration varied considerably across studies, which likely contributed to the substantial levels of heterogeneity. Sensitivity testing of funnel plots did not reveal publication bias.  "," Probiotics may prevent AOM in children not prone to AOM, but the inconsistency of the subgroup analyses suggests caution in interpreting these results. Probiotics decreased the proportion of children taking antibiotics for any infection. The proportion of children experiencing adverse events did not differ between the probiotic and comparator groups. The optimal strain, duration, frequency, and timing of probiotic administration still needs to be established.   ",1,TRUE,FALSE,14,Difference in proportion of children with other infections,RR 0.75 (0.65 to 0.87),3610 (11 RCTs),⊕⊕⊕⊝ MODERATE6,272 per 1000 (236 to 316),RR,3610,NA,0.65,0.87,RR 0.75,Initializing
